August 9, 2018 7:38am

To stay invested, we constantly need to consider share pricing in some downside situations as an opportunity


Earnings: Organovo (ONVO), Histogenics (HSGX), Asterias Biotherapeutics (NYSEMKT: AST), Caladrius Bioscience (CLBS), Stemline Therapeutics (STML), Intrexon (XON) and BioLife Solutions (BLFS)

Pre-open indications: four (4)


Are the realities of “our” universe aligned with circumstance; RMi reports pre-open indications that shed light on share pricing events and today’s session values.

When is it wrong to be right so often?

Be a contender, your portfolio should be profiting from RMi’s analysis!  Want to know WHY?    Subscribe!

Members only. Please login.